Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

2.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group., Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
3.

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.

Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA; CEPAC-International Investigators..

J Infect Dis. 2008 May 1;197(9):1324-32. doi: 10.1086/587184.

4.

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC.

Ann Intern Med. 2008 Feb 5;148(3):178-85.

5.

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.

PMID:
18195565
6.

The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, Gabillard D, Seyler C, Freedberg KA, Anglaret X.

Antivir Ther. 2007;12(4):543-51.

7.

HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.

Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA; CEPAC International Investigators..

AIDS. 2007 May 11;21(8):973-82.

8.

CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group., El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.

9.

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.

N Engl J Med. 2006 Sep 14;355(11):1141-53.

11.

CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment.

Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):464-9.

PMID:
16810113
12.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
13.
14.

Approaches to rationing antiretroviral treatment: ethical and equity implications.

Bennett S, Chanfreau C.

Bull World Health Organ. 2005 Jul;83(7):541-7.

15.

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.

Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA; Global AIDS Policy Model Investigators..

AIDS. 2005 Aug 12;19(12):1299-308.

PMID:
16052085
16.

HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy.

Kress KD.

Am J Health Syst Pharm. 2004 Oct 1;61 Suppl 3:S3-14; quiz S15-6. Review. Erratum in: Am J Health Syst Pharm. 2004 Nov 15;61(22):2350.

PMID:
15503932
17.
18.

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.

Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E.

AIDS. 2004 Apr 9;18(6):887-95.

PMID:
15060436
19.

Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A.

Am J Epidemiol. 2003 Oct 1;158(7):687-94.

PMID:
14507605
20.

Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

Masur H, Kaplan JE, Holmes KK; U.S. Public Health Service.; Infectious Diseases Society of America..

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78.

PMID:
12617574

Supplemental Content

Support Center